CGON CG Oncology, Inc. Common stock
USHealthcareAs of 2026-08-24
Why CGON matters now
CG Oncology, Inc. Common stock (CGON) is a US stock in Healthcare. The latest InvestLog snapshot shows $78.23 with -1.98% on the session and $6.90B in market capitalization; recent performance reads 1-month -3.51% and YTD +47.11%.
The latest financial table shown here is Q1 2026, with revenue of $1.1M, net income of $-60.2M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.0%.
The latest indexable market news headline is "Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $82.00; recent insider activity includes Mulay James filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.73
P/S
1062.40
EV/EBITDA
-29.06
DCF Value
$-3.39
FCF Yield
-3.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-664.8%
Operating Margin
-4239.0%
Net Margin
-3682.6%
ROE
-23.3%
ROA
-16.4%
ROIC
-19.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.1M | $-60.2M | $-0.71 |
| Q4 2025 | $2.3M | $-41.3M | $-0.52 |
| FY 2025 | $4.0M | $-161.0M | $-2.08 |
| Q3 2025 | $1.7M | $-43.8M | $-0.57 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$82.57
Target (Median)
$82.00
Target Range
$70.00 - $93.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.31
CG Oncology Inc. is a biotechnology company in the clinical development stage, committed to advancing and bringing to market an innovative, bladder-sparing core treatment for individuals diagnosed with bladder cancer. Their principal drug candidate, cretostimogene, is presently undergoing clinical evaluation. Its initial focus is on providing a therapeutic option for patients suffering from high-risk Non-Muscle Invasive Bladder Cancer who have not responded to Bacillus Calmette Guerin (BCG) therapy, which represents the established standard of care for this particular severe form of NMIBC.